CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Most importantly, our data revealed that TGF-β1 and BMP treatment and miR-155 down-regulation may act synergistically to exert further anti-proliferative and pro-apoptotic effects on CD34+ CML cells (Figures 4(Fig. 4), 5(Fig. 5)).